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We thank Drs Rashidi and Rahman for their interest in our article and agree that the mechanism by which pravastatin might preserve kidney function is of major scientific interest. The putative renal benefits of statins might be mediated through improved endothelial or cardiac function (improved renal perfusion), 1 reduction in proteinuria, 2 improved serum lipid profile, or some other mechanism such as systemic or intrarenal antiinflammatory actions. 3 Unfortunately, our data do not permit us to conclude which, if any, of these mechanisms are responsible. We agree that data on inflammatory biomarkers after randomization would have been very interesting, especially because baseline markers of inflammation appear to predict renal benefit from pravastatin. 4 However, these measurements have not been done on most of the participants in our analysis.
Drs Rashidi and Rahman correctly point out that baseline low-density lipoprotein cholesterol levels were lower among those with moderate chronic kidney disease. However, as reported in our previous analysis from this data set, 5 the reductions in low-density lipoprotein and total cholesterol caused by pravastatin use were significantly greater among those with estimated glomerular filtration rate Ͻ60 mL/min per 1.73m 2 compared with those with normal renal function. It is thus difficult to conclude that lipid-lowering effects per se were not responsible for the apparent renal benefits of pravastatin, and we agree that further studies are required.
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